-
United Therapeutics reported Q3 2026 revenue of US$832.5 million compared with US$799.5 million a year earlier, while net income and earnings per share were lower year on year as the company increased spending and absorbed mixed product trends.
-
The Board authorized a US$2.0b share repurchase program and has already bought back 8.13% of shares under it, which tightens the share count even as United Therapeutics funds clinical work on Treprostinil, Iloprost SMI and other pipeline assets.
-
We will now see how United Therapeutics' record quarterly revenue, together with this large buyback, could influence its broader investment narrative.
Capitalize on the mix of record United Therapeutics revenue and heavy buybacks by scanning a curated group of resilient healthcare specialists in the 38 healthcare AI stocks .
United Therapeutics Investment Narrative Recap
To stay invested in United Therapeutics, you need to be comfortable with a story where current pulmonary hypertension products fund a push into broader cardiopulmonary disease and organ technologies. The latest quarter showed record revenue but lower earnings per share as expenses rose, so the near term focus stays on execution around Tyvaso, ralinepag and inhalation devices.
The most important short term catalyst remains the 2027 FDA decisions for nebulized Tyvaso in idiopathic pulmonary fibrosis and for ralinepag in pulmonary arterial hypertension. The biggest risk today is that core prostacyclin products face pressure from competitors while real world adoption in larger pulmonary fibrosis and COPD groups falls short of expectations.
The recent Investigational New Drug clearance for Treprostinil Iloprost SMI is the most relevant recent announcement in this context. It indicates that United Therapeutics is still investing heavily in the prostacyclin franchise with an episodic, as needed inhaled option intended to address symptom flare ups between background doses in pulmonary arterial hypertension.
Because this is a phase 1, open label, single ascending dose study, the readthrough to revenue is early, but it matters for catalysts and risk balance. A broader menu of treprostinil and iloprost formulations could help defend share if existing Tyvaso or Orenitram volumes face pressure, while any clinical or tolerability issues would highlight how dependent the long term outlook is on successful execution across multiple delivery platforms.
United Therapeutics' current analyst narrative points to revenues of US$4.5b and earnings of US$1.9b by 2029. That profile is built on an assumed 12.9% yearly revenue growth rate and an earnings increase of about US$600m from US$1.3b today.
Uncover why United Therapeutics' fair value indicates a 10% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
Some of the most optimistic analysts focus on United Therapeutics' organ programs rather than pulmonary drugs. Before this earnings print, the bullish group was modeling about US$5.4b of revenue and US$2.4b of earnings by 2029, far above consensus. You can treat today's record revenue and large buyback as fresh data that might shift those views, and explore how your own expectations compare across that wide range of forecasts.
Explore 3 other United Therapeutics fair value estimates , including one that suggests potential upside of as much as 239% from the current price.
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.
-
A great starting point for your United Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
-
See our latest analysis for United Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate United Therapeutics' overall financial health at a glance.
Looking for more investment ideas beyond United Therapeutics?
If the United Therapeutics story has sharpened your thinking, it can help to cross check those insights against a wider watchlist. The Simply Wall St Screener lets you filter for traits that matter to you, whether that is resilience, income or long term compounding potential.
-
If resilience matters most to you, start with companies that score well on balance sheet strength through the list of solid balance sheet and fundamentals (24 results) .
-
For investors who care about both quality and price, narrow the field to companies that look attractively priced relative to their fundamentals using the 35 high quality undervalued stocks .
-
If steadier cash payouts appeal, build a shortlist of companies with stronger income profiles through the 5 dividend fortresses .
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include UTHR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
